By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BD Diagnostics said today that Italian biotech and molecular diagnostics company Biodiversity will develop and commercialize tests tailored for BD's platform for the detection of infections in transplant patients, as part of a regional collaboration.

Biodiversity will develop a portfolio of molecular assays to run on the BD Max System's open architecture. The assays will be for patients who have undergone transplants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.